Skip to content

Autologous Endometrial Coculture (AECCT)

A Randomized Controlled Trial Evaluating Autologous Endometrial Coculture (AECC) As An Effective Tool For Young Patients With Poor Ovarian Reserve

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01472861
Acronym
AECCT
Enrollment
20
Registered
2011-11-17
Start date
2009-10-31
Completion date
2015-06-30
Last updated
2015-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

coculture, endometrial biopsy, IVF poor responders

Brief summary

The purpose of this study is to determine if the use of Autologous Endometrial Coculture (AECC) in young in vitro fertilization (IVF) patients with poor ovarian reserve improves pregnancy outcome.

Detailed description

Young women with poor ovarian reserve are commonly given a poor prognosis for IVF success. Standard culture media for fertilizing oocytes (unfertilized eggs) is commonly used in IVF which closely resembles tubal fluid. Efforts to create optimal culture conditions for fertilization of human embryos for women with poor quality embryos and/or repeated implantation failures have been developed at our center by using AECC. AECC involves placing a patient's fertilized eggs on top of a layer of cells from her own uterine lining, creating a more natural environment for embryo development and maximizing the chance for IVF pregnancy. The investigators will prospectively randomize young patients (≤ age 38 years) poor ovarian reserve to AECC or no AECC with standard culture media to study pregnancy outcome.

Interventions

PROCEDUREAECC (Autologous endometrial coculture)

endometrial biopsy with autologous endometrial coculture

OTHERno endometrial biopsy or Autologous endometrial coculture (AECC) performed

routine procedures with out biopsy

Sponsors

Weill Medical College of Cornell University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 38 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy women undergoing IVF at CRMI * Age ≤ 38 years * Poor ovarian reserve with antral follicle count less than 6 follicles, cycle day 2/3 FSH \> 12 ng/ml, AMH \< 0.5 ng/ml

Exclusion criteria

* Healthy women undergoing IVF with male factor, severe endometriosis, or tubal factor infertility * Donor patients * Contraindications for the use of gonadotropins (i.e. pregnancy, lactation, undiagnosed vaginal bleeding or ovarian cysts) * Recent or current medical conditions where the patient is not medically stable to undergo stimulation or egg retrieval, HIV infection, diabetes, cardiovascular disease, gastrointestinal, hepatic disease, renal or pulmonary disease. * Any patient who is not a candidate for IVF

Design outcomes

Primary

MeasureTime frame
Pregnancy outcome1 month

Secondary

MeasureTime frame
Embryo quality1 month

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026